Loading...
XIDX
PEHA
Market cap15mUSD
Nov 12, Last price  
326.00IDR
Name

Phapros Tbk PT

Chart & Performance

D1W1MN
XIDX:PEHA chart
P/E
9.77
P/S
0.29
EPS
33.37
Div Yield, %
—
Shrs. gr., 5y
—
Rev. gr., 5y
-0.82%
Revenues
940.88b
+26.34%
470,666,486,000529,752,573,000521,610,950,000578,139,346,000691,246,741,000816,132,595,0001,002,126,037,0001,022,969,624,0001,105,420,197,000980,556,653,0001,051,444,342,0001,168,474,434,0001,014,129,711,000744,694,626,000940,879,809,000
Net income
28.03b
P
64,696,441,00069,159,968,00042,105,371,00045,326,940,00063,007,926,00087,002,410,000125,266,061,000132,306,708,000102,033,530,00048,487,862,00011,070,907,00028,069,871,0005,959,329,000-285,069,165,00028,031,391,000
CFO
70.98b
-49.76%
-27,217,083,00056,903,361,00019,500,898,00084,042,617,00070,089,895,000114,082,652,000102,026,324,000-75,906,305,000-2,481,802,000259,484,562,000189,923,155,00028,069,871,000-14,443,738,000141,277,659,00070,984,560,000
Dividend
Jun 19, 202313.37 IDR/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

PT Phapros, Tbk is a prominent Indonesian company operating within the pharmaceutical and healthcare sectors. Its operations are broadly categorized into four key divisions: Over-the-Counter (OTC) products, Ethical drugs, Generic drug manufacturing, and Toll Manufacturing services. The company's OTC offerings feature well-known brands such as Antimo Anak, Livron B Plek, Noza, Hemorogard, and Bioron. In addition to supplying generic medications to government institutions and hospitals, PT Phapros also serves as a contract manufacturer for other pharmaceutical companies and provides various medical devices. Established in 1954 with its headquarters located in Jakarta, Indonesia, the company further extends its market reach by exporting products internationally. PT Phapros, Tbk functions as a subsidiary under the umbrella of PT Kimia Farma (Persero) Tbk.
URL
https://www.phapros.co.id/
IPO date
Dec 26, 2018
Employees
Domiciled in
ID
Incorporated in
ID

Valuation

Title
IDR in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT